



RESPONSE UNDER 37 C.F.R. §1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1600

#10/B
gnd
6/25/02
(NE)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: WALLACH=12B

RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

In re Application of:)	Conf. No.: 5532
David WALLACH et al)	Art Unit: 1644
Appln. No.: 09/800,909)	Examiner: P. Gambel
Filed: March 8, 2001)	Washington, D.C.
For: TNF RECEPTOR-SPECIFIC)	June 17, 2002
ANTIBODIES)	

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of March 15, 2002,
please amend as follows:

IN THE CLAIMS

Please rewrite claim 13 (amended) in twice-amended
form as follows:

(13 (Twice-amended). A method of inhibiting the
cytotoxic effect of TNF without blocking TNF binding to the
p75 TNF receptor (residues 27-210 of SEQ ID NO:2), comprising
bringing to the vicinity of the p75 TNF receptor a peptide or
antibody comprising the antigen binding portion of an antibody
which binds to the fourth cysteine rich domain of the p75 TNF
receptor, which domain consists of the sequence of amino acid

B1

B